CD274 and melanoma: It highlights a foundational question in drug vs. therapy development in cancer care (for the treatment of melanoma and other malignancies) whether the optimal strategies to combined anti-PD(L)1 treatments should be directed to or guided by anti-cancer vs. immune modulatory modalities.